Login to Your Account



Opexa Gets Boost on Positive Analysis of Tovaxin MS Data

By Catherine Hollingsworth


Wednesday, September 9, 2009
Shares of Opexa Therapeutics Inc. soared 270 percent Tuesday on news of a positive complete analysis of its Phase IIb drug for multiple sclerosis, Tovaxin. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription